In concert with the Fellowship Program Directors Committee and geared toward young physicians, the Core Gynecologic Oncology Series includes foundational lectures from experts covering all gynecologic cancer disease sites and treatment modalities. This library of lectures will continue to be expanded over time. Please see individual lecture presentations for specific topics and lecturers.
This lecture series covers basic roles of genetics, genetic testing and genetic counseling in hereditary breast and ovarian cancer (HBOC), hereditary uterine and colon cancer (Lynch), and integration of hereditary assessment into practice. The lecture includes editorial and best practice discussions with SGO members who have integrated the following successfully into practice:
Hereditary Cancer in a Gynecologic Oncologist Practice: Focus on Breast and Hereditary Cancer
In a Gynecologic Oncologist Practice: Focus on Uterine and Colon
Integrating Hereditary Cancer Assessment into Practice
This lecture series contains several presentations on the topic of palliative care. First, Dr. AK Goodman discusses specific management of cases and the elements that need to be addressed in continuing chemotherapy treatment. Then, Dr. Kerry Rodabaugh discusses guiding patients decisions at end of life. Finally, Dr. Bernadette Craccchiolo discusses assessing pain and ways of managing pain.
The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Genetic counseling for germline mutations and for somatic mutations have both grown exponentially in the last decades. Leading oncologists and genetics stakeholders strongly recommend that qualified oncology providers conduct predictive genetic testing. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.
Continuing Education Language
In support of improving patient care, this activity has been planned and implemented by the Society of Gynecologic Oncology (SGO) and the Advanced Practitioner Society for hematology and Oncology (APSHO). Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SGO designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™ , ANCC or 0.15 CEU for ACPE credits.
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS (AAPA)
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™, from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this activity.
Enduring activity: Start date: October 17, 2017; Expiration date October 16, 2018
Successful Completion:
For successful completion of the continuing education activity, participants must complete the post test with a passing score of 66% and an evaluation.
For Pharmacists:
Pharmacy Universal Activity Number: 0594-0000-17-004-H01-P (knowledge based activity).; 0.15 CEU.
The pharmacists must submit their NABP ePID and DOB to the provider by after completing the online post test and evaluation.
Target Audience
A continuing education activity or nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists and physicians.
Financial Disclosures
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Society of Gynecologic Oncology identified and resolved all conflicts of interest through mechanisms included in the SGO’s Conflict of Interest Resolution Policy.
Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Disclosures FACULTY
Heather Hampel has received consulting fees/honoraria from Beijing Genomics, has equity interests/stock options and has served on the advisory board for Genome Medical, has served on the advisory board for Invitae, and has a financial relationship with Myriad Genetic Labs, Inc.
Paula Anastasia has served on speakers bureaus for Clovis, Genentech, and Merck.
Brianna Hoffner has served as a consultant for Abbott Laboratories, Lilly, and Merck.
Leigha Senter-Jamieson has received consulting fees/honoraria from AstraZeneca, Clovis, and MyGene Counsel; and has served on speakers bureaus for FORCE, LBBC, and AstraZeneca.
Society of Gynecologic Oncology
Teri Jordan, CAE, CMP, has nothing to disclose.
LEAD NURSE PLANNER
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
PLANNERS
Jeannine Coronna has nothing to disclose. Claudine Kiffer has nothing to disclose. Patricia McLafferty has nothing to disclose.
Larry Rosenberg has nothing to disclose. Lynn Rubin has nothing to disclose. Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose. Annie Yueh has nothing to disclose.
This activity is supported with an educational grant by AstraZeneca.
In concert with the Fellowship Program Directors Committee and geared toward young physicians, the Core Gynecologic Oncology Series includes foundational lectures from experts covering all gynecologic cancer disease sites and treatment modalities. This library of lectures will continue to be expanded over time. Please see individual lecture presentations for specific topics and lecturers.
This lecture series covers basic roles of genetics, genetic testing and genetic counseling in hereditary breast and ovarian cancer (HBOC), hereditary uterine and colon cancer (Lynch), and integration of hereditary assessment into practice. The lecture includes editorial and best practice discussions with SGO members who have integrated the following successfully into practice:
Hereditary Cancer in a Gynecologic Oncologist Practice: Focus on Breast and Hereditary Cancer
In a Gynecologic Oncologist Practice: Focus on Uterine and Colon
Integrating Hereditary Cancer Assessment into Practice
This lecture series contains several presentations on the topic of palliative care. First, Dr. AK Goodman discusses specific management of cases and the elements that need to be addressed in continuing chemotherapy treatment. Then, Dr. Kerry Rodabaugh discusses guiding patients decisions at end of life. Finally, Dr. Bernadette Craccchiolo discusses assessing pain and ways of managing pain.
The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Genetic counseling for germline mutations and for somatic mutations have both grown exponentially in the last decades. Leading oncologists and genetics stakeholders strongly recommend that qualified oncology providers conduct predictive genetic testing. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.
Continuing Education Language
In support of improving patient care, this activity has been planned and implemented by the Society of Gynecologic Oncology (SGO) and the Advanced Practitioner Society for hematology and Oncology (APSHO). Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SGO designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™ , ANCC or 0.15 CEU for ACPE credits.
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS (AAPA)
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™, from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this activity.
Enduring activity: Start date: October 17, 2017; Expiration date October 16, 2018
Successful Completion:
For successful completion of the continuing education activity, participants must complete the post test with a passing score of 66% and an evaluation.
For Pharmacists:
Pharmacy Universal Activity Number: 0594-0000-17-004-H01-P (knowledge based activity).; 0.15 CEU.
The pharmacists must submit their NABP ePID and DOB to the provider by after completing the online post test and evaluation.
Target Audience
A continuing education activity or nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists and physicians.
Financial Disclosures
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Society of Gynecologic Oncology identified and resolved all conflicts of interest through mechanisms included in the SGO’s Conflict of Interest Resolution Policy.
Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Disclosures FACULTY
Heather Hampel has received consulting fees/honoraria from Beijing Genomics, has equity interests/stock options and has served on the advisory board for Genome Medical, has served on the advisory board for Invitae, and has a financial relationship with Myriad Genetic Labs, Inc.
Paula Anastasia has served on speakers bureaus for Clovis, Genentech, and Merck.
Brianna Hoffner has served as a consultant for Abbott Laboratories, Lilly, and Merck.
Leigha Senter-Jamieson has received consulting fees/honoraria from AstraZeneca, Clovis, and MyGene Counsel; and has served on speakers bureaus for FORCE, LBBC, and AstraZeneca.
Society of Gynecologic Oncology
Teri Jordan, CAE, CMP, has nothing to disclose.
LEAD NURSE PLANNER
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
PLANNERS
Jeannine Coronna has nothing to disclose. Claudine Kiffer has nothing to disclose. Patricia McLafferty has nothing to disclose.
Larry Rosenberg has nothing to disclose. Lynn Rubin has nothing to disclose. Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose. Annie Yueh has nothing to disclose.
This activity is supported with an educational grant by AstraZeneca.
In concert with the Fellowship Program Directors Committee and geared toward young physicians, the Core Gynecologic Oncology Series includes foundational lectures from experts covering all gynecologic cancer disease sites and treatment modalities. This library of lectures will continue to be expanded over time. Please see individual lecture presentations for specific topics and lecturers.
This lecture series covers basic roles of genetics, genetic testing and genetic counseling in hereditary breast and ovarian cancer (HBOC), hereditary uterine and colon cancer (Lynch), and integration of hereditary assessment into practice. The lecture includes editorial and best practice discussions with SGO members who have integrated the following successfully into practice:
Hereditary Cancer in a Gynecologic Oncologist Practice: Focus on Breast and Hereditary Cancer
In a Gynecologic Oncologist Practice: Focus on Uterine and Colon
Integrating Hereditary Cancer Assessment into Practice
This lecture series contains several presentations on the topic of palliative care. First, Dr. AK Goodman discusses specific management of cases and the elements that need to be addressed in continuing chemotherapy treatment. Then, Dr. Kerry Rodabaugh discusses guiding patients decisions at end of life. Finally, Dr. Bernadette Craccchiolo discusses assessing pain and ways of managing pain.
The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Genetic counseling for germline mutations and for somatic mutations have both grown exponentially in the last decades. Leading oncologists and genetics stakeholders strongly recommend that qualified oncology providers conduct predictive genetic testing. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.
Continuing Education Language
In support of improving patient care, this activity has been planned and implemented by the Society of Gynecologic Oncology (SGO) and the Advanced Practitioner Society for hematology and Oncology (APSHO). Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SGO designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™ , ANCC or 0.15 CEU for ACPE credits.
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS (AAPA)
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™, from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this activity.
Enduring activity: Start date: October 17, 2017; Expiration date October 16, 2018
Successful Completion:
For successful completion of the continuing education activity, participants must complete the post test with a passing score of 66% and an evaluation.
For Pharmacists:
Pharmacy Universal Activity Number: 0594-0000-17-004-H01-P (knowledge based activity).; 0.15 CEU.
The pharmacists must submit their NABP ePID and DOB to the provider by after completing the online post test and evaluation.
Target Audience
A continuing education activity or nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists and physicians.
Financial Disclosures
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Society of Gynecologic Oncology identified and resolved all conflicts of interest through mechanisms included in the SGO’s Conflict of Interest Resolution Policy.
Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Disclosures FACULTY
Heather Hampel has received consulting fees/honoraria from Beijing Genomics, has equity interests/stock options and has served on the advisory board for Genome Medical, has served on the advisory board for Invitae, and has a financial relationship with Myriad Genetic Labs, Inc.
Paula Anastasia has served on speakers bureaus for Clovis, Genentech, and Merck.
Brianna Hoffner has served as a consultant for Abbott Laboratories, Lilly, and Merck.
Leigha Senter-Jamieson has received consulting fees/honoraria from AstraZeneca, Clovis, and MyGene Counsel; and has served on speakers bureaus for FORCE, LBBC, and AstraZeneca.
Society of Gynecologic Oncology
Teri Jordan, CAE, CMP, has nothing to disclose.
LEAD NURSE PLANNER
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
PLANNERS
Jeannine Coronna has nothing to disclose. Claudine Kiffer has nothing to disclose. Patricia McLafferty has nothing to disclose.
Larry Rosenberg has nothing to disclose. Lynn Rubin has nothing to disclose. Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose. Annie Yueh has nothing to disclose.
This activity is supported with an educational grant by AstraZeneca.
This three-day course offers clinicians a collegial environment to discuss current issues in treating women with gynecologic cancers. Topics include complementary medicine, ovarian cancer, minimally invasive surgery and innovative uses of technology. An interactive case-based tumor board session will promote clinical, interpersonal, and scientific engagement, allowing practitioners to directly apply knowledge from this educational session to their research and practice. The Winter Meeting is ideal for young and experienced physicians alike, as well as all members of the women’s cancer care team.
The Annual Meeting on Women's Cancer is intended for gynecologic oncologists, medical oncologists, radiation oncologists, obstetricians/gynecologists, fellows and residents, research scientists, nurses, nurse practitioners, physician assistants, allied health professionals, and others involved in the care of patients with gynecologic malignancies.
This journal review series consist of peer-reviewed articles that have been abstracted by experts in the field and includes multiple choice questions for each abstracted journal.
Society of Gynecologic Oncologists (SGO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. SGO designates this educational activity for a maximum of 1.0 AMA PRA category 1 credit(s) ™ for each individual journal abstract. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Annual Meeting on Women's Cancer is intended for gynecologic oncologists, medical oncologists, radiation oncologists, obstetricians/gynecologists, fellows and residents, research scientists, nurses, nurse practitioners, physician assistants, allied health professionals, and others involved in the care of patients with gynecologic malignancies.
The Annual Meeting on Women's Cancer is intended for gynecologic oncologists, medical oncologists, radiation oncologists, obstetricians/gynecologists, fellows and residents, research scientists, nurses, nurse practitioners, physician assistants, allied health professionals, and others involved in the care of patients with gynecologic malignancies.
The SGO Annual Meeting continues to be the premier medical conference on the prevention, research, and comprehensive management of gynecologic malignancies. This educational events includes the most up to date clinical studies and translational research that will be of interest across the spectrum of our SGO membership, including our multidisciplinary, Allied health, and international attendees.
The 2014 program highlights global health, genetics, stress management, quality of care, and payment reform, along with educational forums and seminars covering the following topics:
Special Interest Session I - Seminal and International Clinical Trials
The Annual Meeting on Women's Cancer is intended for gynecologic oncologists, medical oncologists, radiation oncologists, obstetricians/gynecologists, fellows and residents, research scientists, nurses, nurse practitioners, physician assistants, allied health professionals, and others involved in the care of patients with gynecologic malignancies.
Cookies are small pieces of information that are stored by your browser on your computer’s hard drive.
This website uses cookies to enhance the convenience and use of the site, and has placed cookies already.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
By using this site, you agree to our use of cookies.
For more information, including instructions on how to remove the cookies that have been placed,
see our Privacy Policy.
